Table 4. Predictors of pathological complete response.
|
Univariate analysis |
Multivariate analysis |
|||||
|---|---|---|---|---|---|---|
| Factor | ORa | 95% CI | P-value | ORa | 95% CI | P-value |
| Age (years) |
0.99 |
0.98–1 |
0.2 |
1 |
0.99–1.01 |
0.8 |
|
Multifocal tumoura | ||||||
| No | 1.00 | — | — | 1.00 | — | — |
| Yes |
0.69 |
0.48–1 |
0.05 |
0.75 |
0.5–1.12 |
0.15 |
|
Nuclear grade | ||||||
| I | 1.00 | — | — | 1.00 | — | — |
| II | 4.91 | 0.67–36.14 | 0.1 | 2.91 | 0.38–22.56 | 0.31 |
| III |
20.33 |
2.81–147.17 |
0.002 |
11.26 |
1.47–86.39 |
0.01 |
|
Baseline T stage | ||||||
| T1–T2 | 1.00 | — | — | 1.00 | — | — |
| T3–T4 |
0.69 |
0.51–0.93 |
0.01 |
0.65 |
0.46–0.92 |
0.01 |
|
Baseline N stage | ||||||
| N0 | 1.00 | — | — | 1.00 | — | — |
| N1 or sup |
0.73 |
0.56–0.96 |
0.02 |
0.66 |
0.49–0.9 |
0.008 |
|
Histological subtype | ||||||
| IDC | 1.00 | — | — | 1.00 | — | — |
| ILC |
0.21 |
0.09–0.47 |
<0.001 |
0.5 |
0.19–1.3 |
0.1 |
|
Neoadjuvant chemotherapy regimen | ||||||
| Taxane basedb | 2.67 | 1.56–4.59 | <0.001 | 2.14 | 1.2–3.84 | 0.01 |
| Traztuzumabc | 6 | 4.44–8.12 | <0.001 | 5.03 | 3.64–6.95 | <0.001 |
Abbreviations: CI=confidence interval; IDC=invasive ductal carcinoma; ILC=invasive lobular carcinoma; OR=odds ratio; pCR=pathological complete response.
a
OR=1 is the reference; OR<1, factor associated with lower pCR rate; OR>1, factor associated with higher pCR rate.
b
Taxane-based regimen was compared with no taxane-based regimen.
c
Trastuzumab regimen was compared with no trastuzumab regimen.